Promedior to Present at the Cowen and Company 33rd Annual Health Care Conference
LEXINGTON, Mass., February 27, 2013 — Promedior
, Inc., a clinical stage
biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that Suzanne L. Bruhn, Ph.D., Promedior's President and CEO, is scheduled to present at the Cowen and Company 33rd Annual Health Care Conference in Boston on Monday, March 4, 2013 at 2:00 p.m. ET.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis. Fibrosis is a harmful process that occurs in many diseases, when normal healthy tissue is replaced with excessive scar tissue, compromising function and ultimately leading to organ failure. Promedior's proprietary platform is based upon Pentraxin-2, a naturally-occurring human protein that is specifically active at the site of tissue damage and works as an agonist, potentially preventing and reversing fibrosis.
By acting as a master regulator upstream in the fibrosis cascade, Pentraxin-2 therapeutics harness the innate healing power of the immune system and open up new potential to treat a wide range of systemic fibrotic diseases for which there are no approved therapies. Promedior has successfully advanced lead therapeutic candidates in human clinical trials, and is initially focused on rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF) and myelofibrosis, and fibrovascular retinal diseases, such as Age Related Macular Degeneration (AMD). Promedior is backed by leading global healthcare venture investors, has a significant intellectual property estate relating to the discoveries and applications of Pentraxin-2 therapeutics and is led by an experienced management team. For additional information about Promedior, please visit www.promedior.com
The Yates Network